CAR T-Cell Therapy Market to Reach Valuation of USD 5.9 Billion by 2030 – Surge in Demand for Effective Cancer Treatments and Favourable Reimbursement Policies in Certain Countries Drives the Market

In terms of revenue, the Global Car T-cell Therapy Market is expected to reach by 2030, growing at a CAGR (Compound Annual Growth Rate) of 14.6% from 2023 to 2030.

Car T-cell Therapy is an innovative form of cancer treatment where healthcare providers modify T-cells in a laboratory setting and subsequently introduce them into the cancer patient's body. This enables the T-cells to locate and eradicate cancer cells. By training the immune system to identify cancerous cells, Car T-cell Therapy is considered a type of gene or cell therapy. It is employed to strengthen the immune system's ability to combat cancer.

The advantages of CAR T-cell therapies compared to traditional drugs include using the patient's immune system to destroy cancer cells, resulting in faster recovery and shorter treatment times. Moreover, Car T-cell Therapy remains effective in the body for an extended period, as it can identify and target cancer cells even if the cancer returns. This type of therapy is primarily utilized for treating blood cancers such as lymphoma, acute lymphocytic leukemia, and multiple myeloma. Due to its numerous benefits over conventional drugs, Car T-cell Therapy products are experiencing a high adoption rate, leading to the growth of the Car T-cell Therapy market.

Key Highlights from the Report

• Based on the segment of Drug Type, Axicabtagene Ciloleucel class dominates the Car T-cell Therapy market owing to the increase in adoption of (Yescarta) Axicabtagene Ciloleucel medicine.
• Based on the Indication segment, the Lymphoma category accounted for the substantial growth of the market in 2022 owing to the higher number of approved CAR T-cell therapeutics for treating different forms of lymphoma with a large target population.
• Based on the segment of the End Users, the Hospital division dominated the market in 2022 owing to the well-equipped operation theatre, higher buying power, and rise in patient admission.
• Based on Region, North America holds the significant market share within the Car T-cell Therapy market in 2022 owing to the prominence of important players, the accessibility of licensed medicines, and the increased use of CAR T cell therapies.

Market Dynamics

The surge in demand for effective cancer treatments, the growing prevalence of cancer, favorable reimbursement policies in certain countries, and increased awareness about Car T-cell Therapy are the key drivers of the Car T-cell Therapy market. The market is expanding as a result of the recent launch of commercially available CAR-T cell therapies and the rise of clinical trials, which present encouraging prospects for market expansion. The rising occurrences of lymphoma and leukemia, together with the rising frequency of multiple myeloma cancer, are other contributing factors to the market's growth. Products for CAR T-cell treatment have become more widely used as a result of this. This has led to a greater adoption of Car T-cell Therapy products. For example, the LEUKEMIA and LYMPHOMA SOCIETY have estimated that in 2021, there would be around 34,920 new cases of myeloma in the U.S., with 19,320 cases in males and 15,600 cases in females. Additionally, there are approximately 138,415 people currently living with or in remission from myeloma in the U.S. Similarly, the LEUKEMIA and LYMPHOMA SOCIETY states that in 2021, there will be around 61,090 new cases of leukemia in the U.S., and approximately 397,501 people currently living with or in remission from leukemia in the U.S.

The market for Car T-cell Therapy in North America has grown significantly in recent years and is predicted to keep growing. North America has a high burden of cancer, with a large number of patients seeking effective treatment options. Car T-cell Therapy offers a promising solution for patients with certain types of cancer that have not responded to traditional therapies. A number of CAR T-cell therapies have been authorized by the US FDA to treat different forms of cancer. This regulatory support has contributed to the growth of the market and increased patient access to innovative therapies. Furthermore, the effectiveness and safety of CAR T-cell therapies have been enhanced by developments in genetic engineering and cell therapy methods. These advancements have led to better patient outcomes and increased adoption of this therapy in clinical practice. 

The Global Car T-cell Therapy Market is Segmented as follows

• Drug Type
  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Other Drug Types
• Indication
  • Lymphoma
  • Acute Lymphocytic Leukemia
  • Other Indications
• End User
  • Hospitals
  • Cancer Treatment Centers
• Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

List of the Key Players of the Global Car T-cell Therapy Market is

Celgene Corporation (U.S.), Cartesian Therapeutics Inc. (U.S.), Miltenyi Biotech (Germany), Autolus Therapeutics (UK), Caribou Biosciences Inc. (U.S.), Gilead Sciences Inc. (U.S.), Merck & Co. Inc. (U.S.), Intellia Therapeutics (U.S.), Juno Therapeutics Inc. (U.S.), Bristol-Myers Squibb (U.S.), Novartis AG (Switzerland), Bluebird Bio Inc. (U.S.), Sorrento Therapeutics Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis (France), Celyad Oncology (Belgium) 

The Global Car T-cell Therapy Market Scope can be Tabulated as below